
    
      This study is designed as a randomised, double-blind, placebo-controlled, parallel group
      study to evaluate the safety and tolerability of ToleroMune Ragweed in ragweed allergic
      subjects with allergic rhinoconjunctivitis,subjects may also have controlled asthma. The
      efficacy of ToleroMune Ragweed will be explored in subjects using an(Environmental Exposure
      Chamber)EEC.

      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a
      maximum of 12 weeks before randomisation and may consist of one or two visits to the clinic,
      at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEC at
      least 3 days before randomisation.

      In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be
      randomised to one of five groups and will receive treatment every 2 weeks (Â±2 days) for 14
      weeks.

      In Period 3, Post Treatment Challenge will consist of 4 visits to the EEC 18-22 weeks after
      the first administration in the treatment period and assessments will be performed identical
      to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC.
    
  